FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2912758634> ?p ?o ?g. }

• W2912758634 endingPage "S1546" @default.
• W2912758634 startingPage "S1546" @default.
• W2912758634 abstract "Introduction: Constipation-predominant Irritable Bowel Syndrome (IBS-C) is a common disorder with a reported prevalence of 16% in N America. Alteration of the gut microbiome may result in altered GI motility observed in patients with IBS-C, playing a role in the disease pathogenesis. Eradication of bacterial overgrowth causing dysbiosis can result in some normalization of motility, while the use of fecal microbiota transplantation (FMT) can provide an effective and low-risk therapy. The orally administered encapsulated lyophilized FMT product is preferable to colonoscopically or enema-infused therapy. Here, we report the novel use of encapsulated lyophilized full-spectrum microbiota (LFSM) in treating a patient with severe IBS-C accompanied by chronic fatigue syndrome. Case Report: A 26 y/o female with a 6 y history of GI symptoms presented with bowel opening every 3-5 days, severe straining, difficulty passing a motion, continuous abdominal pain of moderate severity and bloating (Table 1). Furthermore, the patient complained of chronic fatigue, inability to concentrate with marked “brain fog”. She was bed-ridden, unable to continue work for the last 6 months, or travel. Collection of stool for LFSM production was carried out as per AGA Consensus Guidelines. Stool was homogenized with cryoprotectant and the resulting slurry was lyophilized and encapsulated in DR gel capsules containing ˜1.6 x 1011 viable cells/capsule. The patient was treated with a total of 138 capsules over a 12-week induction period. During this period, symptom questionnaires were collected and stools cultured for pathogens to assess efficacy and safety of the LFSM treatment. Discussion of Findings: The patient noted significant improvement in symptoms commencing at week 2. By week 12, numerous symptoms including abdominal discomfort/pain improved and chronic fatigue symptoms ceased. There was a marked increase in energy levels and appetite, resulting in successful completion of half marathons. She is able to travel, recommenced work, and no longer notices “brain fog”. Overall, her QoL improved dramatically by post-treatment and is currently continuing on maintenance. The LFSM treatment appears to have normalized the gut microbiome and the therapy has shown to be efficacious and safe for the last 16 weeks of treatment. With CFS being very difficult to treat, this patients' response to treatment shows that the gut microbiome can be a cause of severe fatigue.Figure: Pre and post-treatment symptom severity for IBS-C patient treated with LFSM." @default.
• W2912758634 created "2019-02-21" @default.
• W2912758634 creator A5042387310 @default.
• W2912758634 creator A5050402462 @default.
• W2912758634 creator A5059070507 @default.
• W2912758634 creator A5085842695 @default.
• W2912758634 date "2017-10-01" @default.
• W2912758634 modified "2023-10-14" @default.
• W2912758634 title "Patient with Severe Constipation-Predominant Irritable Bowel Syndrome Successfully Treated With Encapsulated Lyophilized Full Spectrum Microbiota: A Case Study" @default.
• W2912758634 doi "https://doi.org/10.14309/00000434-201710001-02891" @default.
• W2912758634 hasPublicationYear "2017" @default.
• W2912758634 type Work @default.
• W2912758634 sameAs 2912758634 @default.
• W2912758634 citedByCount "0" @default.
• W2912758634 crossrefType "journal-article" @default.
• W2912758634 hasAuthorship W2912758634A5042387310 @default.
• W2912758634 hasAuthorship W2912758634A5050402462 @default.
• W2912758634 hasAuthorship W2912758634A5059070507 @default.
• W2912758634 hasAuthorship W2912758634A5085842695 @default.
• W2912758634 hasConcept C126322002 @default.
• W2912758634 hasConcept C2776530707 @default.
• W2912758634 hasConcept C2776956441 @default.
• W2912758634 hasConcept C2777165150 @default.
• W2912758634 hasConcept C2778271842 @default.
• W2912758634 hasConcept C2779134260 @default.
• W2912758634 hasConcept C2780955771 @default.
• W2912758634 hasConcept C2781112942 @default.
• W2912758634 hasConcept C71924100 @default.
• W2912758634 hasConcept C90924648 @default.
• W2912758634 hasConceptScore W2912758634C126322002 @default.
• W2912758634 hasConceptScore W2912758634C2776530707 @default.
• W2912758634 hasConceptScore W2912758634C2776956441 @default.
• W2912758634 hasConceptScore W2912758634C2777165150 @default.
• W2912758634 hasConceptScore W2912758634C2778271842 @default.
• W2912758634 hasConceptScore W2912758634C2779134260 @default.
• W2912758634 hasConceptScore W2912758634C2780955771 @default.
• W2912758634 hasConceptScore W2912758634C2781112942 @default.
• W2912758634 hasConceptScore W2912758634C71924100 @default.
• W2912758634 hasConceptScore W2912758634C90924648 @default.
• W2912758634 hasLocation W29127586341 @default.
• W2912758634 hasOpenAccess W2912758634 @default.
• W2912758634 hasPrimaryLocation W29127586341 @default.
• W2912758634 hasRelatedWork W102111670 @default.
• W2912758634 hasRelatedWork W2057226727 @default.
• W2912758634 hasRelatedWork W2058150145 @default.
• W2912758634 hasRelatedWork W2065849014 @default.
• W2912758634 hasRelatedWork W2086642698 @default.
• W2912758634 hasRelatedWork W2098294301 @default.
• W2912758634 hasRelatedWork W2113107751 @default.
• W2912758634 hasRelatedWork W2147533789 @default.
• W2912758634 hasRelatedWork W2978863793 @default.
• W2912758634 hasRelatedWork W3085016254 @default.
• W2912758634 hasVolume "112" @default.
• W2912758634 isParatext "false" @default.
• W2912758634 isRetracted "false" @default.
• W2912758634 magId "2912758634" @default.
• W2912758634 workType "article" @default.